European drug approvals: amprenavir, ddI EC, Trizivr and Kaletra
16 August 2000. Related: Antiretrovirals.
Antiretrovirals
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily
16 July 2000. Related: Antiretrovirals.
Didanosine systemic exposure in children similar with or without food, high interpatient variability suggests TDM to titrate individual dosages
15 June 2000. Related: Antiretrovirals, Paediatric care.
Low level HIV replication despite good virological response may explain CD4+ cell decline in a patient receiving combination nucleoside analogue therapy
15 June 2000. Related: Antiretrovirals, Basic science and immunology.
ABT-378/r (lopinavir) now available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Enteric coated ddI available on named patient basis in UK
15 May 2000. Related: Antiretrovirals.
Nelfinavir potency concerns
15 May 2000. Related: Antiretrovirals.